New form of brachytherapy shows promise

The decision to withdraw sacituzumab govitecan from the market was made in consultation with the US FDA following negative data from the phase 3 TROPiCS-04 trial.

In this episode, Robert E. Brannigan, MD, and Juan J. Andino, MD, MBA, discuss the recent amendment to the AUA/ASRM guideline on male infertility.

SMSNA 2024 abstract data show shockwave therapies and platelet-rich plasma, either alone or in combination, may be promising treatments for ED.

In this episode of Speaking of Urology®, Ashley G. Winter, MD, discusses the use of vaginal estrogen.

“The take-home message…is it doesn't matter whether you put the reservoir in the ectopic location or the prevesical location. Patients tend to be satisfied in both locations,” said Mohit Khera, MD, MBA, MPH.

The investigators reported a significantly greater prevalence of ED in men with BPH (P < .0001).